ProMIS Neurosciences (PMN)
NASDAQ:PMN
Want to see PMN full AI Analyst Report?
Top Page
ProMIS Neurosciences
(NASDAQ:PMN)
Select Model
Select Model
Rating:45Neutral
Price Target:
$9.50
▲(17.00% Upside)
Action:Reiterated
Date:05/21/26
The score is primarily held back by weak financial performance (no revenue, large ongoing losses, and continued cash burn despite no debt). Technicals also remain bearish with the price below key moving averages and negative MACD, while valuation is constrained by unprofitability. Corporate events are modestly supportive operationally but include potential dilution.
Positive Factors
Low leverage and meaningful equity base
A debt-free balance sheet with roughly $60.7M of equity versus ~$67.4M in assets provides structural financial flexibility. For a clinical-stage biotech this reduces bankruptcy and interest burden risk, enabling the company to fund R&D and pursue trials without immediate leverage constraints.
Negative Factors
Pre-revenue with large trailing net losses
Being pre-revenue while incurring sizeable recurring losses is a fundamental constraint: the company must rely on external funding to sustain operations and advance trials. Persistent deficits materially raise financing needs, increase execution risk, and can delay programs if capital is scarce.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and meaningful equity base
A debt-free balance sheet with roughly $60.7M of equity versus ~$67.4M in assets provides structural financial flexibility. For a clinical-stage biotech this reduces bankruptcy and interest burden risk, enabling the company to fund R&D and pursue trials without immediate leverage constraints.
Read all positive factors
ProMIS Neurosciences (PMN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.03M
Dividend YieldN/A
Average Volume (3M)819.50K
Price to Earnings (P/E)―
Beta (1Y)0.21
Revenue GrowthN/A
EPS Growth-1753.64%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-23.59
Shares Outstanding2,152,397
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-426.74
Enterprise Value/Market Cap-2.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.21
Forecast
1Y Price Target
$32.00Price Target Upside294.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-5.3
Revenue Forecast (FY)N/A
ProMIS Neurosciences Business Overview & Revenue Model
Company Description
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple syst...
How the Company Makes Money
null...
ProMIS Neurosciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ― |
| Gross Profit | 0.00 | 0.00 | 0.00 | -10.44M | 0.00 | ― |
| EBITDA | -41.02M | -39.72M | 2.86M | -17.81M | -17.77M | -9.33M |
| Net Income | -40.62M | -39.72M | 2.78M | -17.51M | -18.06M | ― |
Balance Sheet | ||||||
| Total Assets | 67.41M | 9.18M | 18.91M | 13.62M | 9.38M | 22.44M |
| Cash, Cash Equivalents and Short-Term Investments | 63.85M | 6.15M | 13.32M | 12.63M | 8.01M | 21.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.94M |
| Total Liabilities | 6.69M | 10.44M | 2.42M | 9.87M | 11.20M | 15.28M |
| Stockholders Equity | 60.72M | -1.26M | 16.49M | 3.75M | -1.82M | 7.16M |
Cash Flow | ||||||
| Free Cash Flow | -35.47M | -28.12B | -27.18M | -10.84M | -17.04M | -9.45M |
| Operating Cash Flow | -35.47M | -28.12B | -27.18M | -10.84M | -17.03M | -9.44M |
| Investing Cash Flow | -703.00 | -702.00K | -693.00 | -1.35K | -1.98K | 95.93K |
| Financing Cash Flow | 91.07M | 20.94B | 27.88M | 17.75M | 6.49M | 25.63M |
ProMIS Neurosciences Technical Analysis
Neutral
8.12
Price Trends
10.85
Negative
13.69
Negative
11.78
Negative
Market Momentum
-0.31
Negative
48.04
Neutral
67.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMN, the sentiment is Neutral. The current price of 8.12 is below the 20-day moving average (MA) of 10.31, below the 50-day MA of 10.85, and below the 200-day MA of 11.78, indicating a neutral trend. The MACD of -0.31 indicates Negative momentum. The RSI at 48.04 is Neutral, neither overbought nor oversold. The STOCH value of 67.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PMN.
ProMIS Neurosciences Risk Analysis
ProMIS Neurosciences disclosed 80 risk factors in its most recent earnings report. ProMIS Neurosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProMIS Neurosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $23.03M | -1.66 | 9999.00% | ― | ― | -1753.64% | |
44 Neutral | $215.24M | -0.48 | 359.80% | ― | ― | -3629.03% | |
44 Neutral | $8.98M | -2.01 | -49.00% | ― | 11.90% | 43.46% | |
44 Neutral | $26.12M | -2.87 | 9999.00% | ― | ― | ― | |
42 Neutral | $63.40M | -1.21 | -318.08% | ― | ― | 20.55% |
* Healthcare Sector Average
PMN
ProMIS Neurosciences
10.35
-2.64
-20.30%
NERV
Minerva Neurosciences
4.51
2.71
150.56%
IMRN
Immuron
1.19
-0.54
-31.21%
ANVS
Annovis Bio
1.78
-1.03
-36.65%
NRSN
Neurosense Therapeutics Ltd.
0.74
-1.65
-69.12%
ProMIS Neurosciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
ProMIS Neurosciences shareholders approve directors and incentive plan
Positive
May 20, 2026
On May 20, 2026, ProMIS Neurosciences held its Annual Meeting, at which shareholders representing approximately 53.1% of outstanding common shares were present or represented by proxy. Investors elected seven directors to serve until the 2027 annu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.